AstraZeneca Results Presentation Deck
TROPION-Lung01
Dato-DXd in 2-3L advanced NSCLC
Statistically significant PFS benefit
Favourable early OS trend
All grade ILD consistent with previous
Dato-DXd trials
Oncology - R&D highlights
TROPION-Lung01 reinforces importance of Dato-DXd in NSCLC and beyond
Some Grade 5 ILD cases observed
No new safety signals
CEO Opening Remarks
Proceeding to file data with FDA
Lung
cancer
Breast
cancer
Financial Results
Other
tumours
Replace CTX as
monotherapy
TROPION-Lung01
2-3L NSCLC w/ and w/o AGAS
TROPION-Lung05
2L+ NSCLC w/ AGA
TROPION-Breast01
2L+ HR+ HER2- mBC
TROPION-Breast02
1L PD-L1- aTNBC¹
Oncology
TROPION-PanTumor01
advanced solid tumours
BioPharmaceuticals
H2
Further outcomes with
novel combinations
TROPION-Lung02
+ pembro + platinum CTX |
1-3L NSCLC w/o AGAS
TROPION-Lung04
+ Imfinzi / rilvegostomig / volrustomig
+ carbo | 1-2L NSCLC w/o AGAS
TROPION-Lung07
+ pembro + platinum CTX |
1L PD-L1<50% NSCLC w/o AGAS
TROPION-Lung08
+ pembro |
1L PD-L1250% NSCLC w/o AGAS
ORCHARD
+ Tagrisso | EGFRm 2L NSCLC
Rare Disease
BEGONIA
+ Imfinzi | 1L a TNBC
TROPION-Breast03
+ Imfinzi | adjuvant eTNBC
TROPION-PanTumor03
+/- combinations | advanced solid tumours
AVANZAR
+ Imfinzi + carbo | 1L NSCLC w/o AGAS
Assess predictive value of
TROP2 biomarker
CEO Closing Remarks
Solid colour indicates Phase III trial; outline only indicates Phase I or II trial. Lung studies in the locally advanced / metastatic setting.
1. or not candidate for PD-(L)1 therapy for another reason. Dato-DXd = datopotamab deruxtecan; NSCLC = non-small cell lung cancer; PFS = progression free survival; OS = overall survival; ILD = interstitial lung disease; FDA = US Food
and Drug Administration; AGA = actionable genomic alterations; pembro = pembrolizumab; CTx = chemotherapy; carbo = carboplatin; PD-L1 = programmed cell death ligand 1; EGFRm = epidermal growth factor receptor mutation;
18 mBC = metastatic breast cancer; HR+ = hormone receptor positive; HER2- = human epidermal growth factor receptor negative; aTNBC = advanced triple negative breast cancer; eTNBC = early triple negative breast cancer.
Collaboration partners: Daiichi Sankyo (Dato-DXd)View entire presentation